Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Chief Medical Officer | October 15, 2020 | October 19, 2020 |
| Korro Bio, Inc.KRRO · Entity 6388 | Director | June 10, 2026 | June 11, 2026 |
| Marker Therapeutics, Inc.MRKR · Entity 7609 | Director | November 17, 2025 | November 19, 2025 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 05, 2025 | June 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kaleido Biosciences, Inc.
Report date October 15, 2020 · Filed October 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.69 · Expires 2030-10-14 | Direct | 67,500 |
Reported balance
After 2020-10-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-15 · Grant · Acquired 67,500 · Balance 67,500 F1: 25% of this option shall vest on October 15, 2021, with the remainder vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest on October 15, 2021, with the remainder vesting in 12 equal quarterly installments thereafter.
Korro Bio, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 · Expires 2036-06-09 | Direct | 14,677 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 14,677 · Balance 14,677 F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.
Marker Therapeutics, Inc.
Report date November 17, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2035-11-17 | Direct | 84,411 |
Reported balance
After 2025-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-17 · Grant · Acquired 84,411 · Balance 84,411 F1: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2035-11-17 | Direct | 137,330 |
Reported balance
After 2025-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-17 · Grant · Acquired 137,330 · Balance 137,330 F2: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
F2: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
PLIANT THERAPEUTICS, INC.
Report date June 05, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2035-06-05 | Direct | 30,000 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 30,000 · Balance 30,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARENA PHARMACEUTICALS INC
Report date March 11, 2022 · Filed March 11, 2022
Section 16 reporting ended · disclosed 2022-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-11 · Other · Disposed 2,939 · Balance 3,882 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Row 2 · 2022-03-11 · Other · Disposed 3,882 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-11 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.19 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-11 · Disposition to issuer · Disposed 7,202 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 22:01 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 14,677 | $0.00 Strike: $10.59 | $0.00 |
DisclosureSEC source: 0001193125-26-268001 · ownership.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,677 Underlying: Common Stock · 14,677 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:18 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (Right to Buy) · Derivative | 137,330 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001768011-25-000003 · primary_doc.xml · derivative · entry 2 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,330 Underlying: Common Stock · 137,330 shares Expires 2035-11-17 F2 · derivative.exercise_date: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:18 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (Right to Buy) · Derivative | 84,411 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001768011-25-000003 · primary_doc.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,411 Underlying: Common Stock · 84,411 shares Expires 2035-11-17 F1 · derivative.exercise_date: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:26 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 6,010 | $0.00 Strike: $14.87 | $0.00 |
DisclosureSEC source: 0000950170-25-085435 · ownership.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,010 Underlying: Common Stock · 6,010 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. Read SEC document |
| June 05, 2025 Filed Jun 10, 2025 00:44 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001746473-25-000131 · wk-form4_1749516267.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:19 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001104659-25-014318 · tm256716-6_4seq1.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-02-12 F1 · shares: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025. F1 · derivative.exercise_date: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 23:14 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 9,041 | $0.00 Strike: $49.00 | $0.00 |
DisclosureSEC source: 0000950170-24-101535 · ownership.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,041 Underlying: Common Stock · 9,041 shares Expires 2034-08-25 F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments commencing from August 26, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 13, 2024 Filed Jun 18, 2024 00:16 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 26,764 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001746473-24-000107 · wk-form4_1718669781.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,764 Underlying: Common Stock · 26,764 shares Expires 2034-06-13 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 21:19 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $23.09 | $0.00 |
DisclosureSEC source: 0001209191-23-035533 · doc4.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:34 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-23-035616 · doc4.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 22:08 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $24.23 | $0.00 |
DisclosureSEC source: 0001140361-22-033663 · form4.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-09-13 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of September 14, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:10 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001209191-22-032172 · doc4.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-05-23 F1 · derivative.exercise_date: This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:23 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 7,202 | Not disclosed Strike: $65.19 | Not disclosed |
DisclosureSEC source: 0001628280-22-005914 · wf-form4_164703379738312.xml · derivative · entry 5 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,202 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:23 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $61.31 | Not disclosed |
DisclosureSEC source: 0001628280-22-005914 · wf-form4_164703379738312.xml · derivative · entry 4 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:23 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 2,500 | Not disclosed Strike: $61.31 | Not disclosed |
DisclosureSEC source: 0001628280-22-005914 · wf-form4_164703379738312.xml · derivative · entry 3 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:23 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 3,882 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-005914 · wf-form4_164703379738312.xml · nonDerivative · entry 2 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:23 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 2,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-005914 · wf-form4_164703379738312.xml · nonDerivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,882 F1 · kind: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. F1 · price: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 22:20 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-21-068837 · doc4.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: This option vests in equal monthly installments over a three-year period commencing on January 8, 2022, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:28 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 7,202 | $0.00 Strike: $65.19 | $0.00 |
DisclosureSEC source: 0001628280-21-012285 · wf-form4_162379245757011.xml · derivative · entry 2 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,202 Underlying: Common Stock · 7,202 shares Expires 2028-06-11 F2 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 11, 2021 with the final installment vesting upon the earlier of the one-year anniversary of the grant date or the date of the next annual stockholders' meeting, and are exercisable once vested. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:28 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 3,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012285 · wf-form4_162379245757011.xml · nonDerivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,821 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 11, 2022, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 07:38 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 67,500 | $0.00 Strike: $8.69 | $0.00 |
DisclosureSEC source: 0001209191-20-055208 · doc4.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2030-10-14 F1 · derivative.exercise_date: 25% of this option shall vest on October 15, 2021, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:38 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $61.31 | $0.00 |
DisclosureSEC source: 0001209191-20-037101 · doc4.xml · derivative · entry 4 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-12 F4 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 12, 2020, and are exercisable once vested. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:38 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $61.31 | $0.00 |
DisclosureSEC source: 0001209191-20-037101 · doc4.xml · derivative · entry 3 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2027-06-12 F3 · derivative.exercise_date: The options vest in 36 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over three years beginning on July 12, 2020, and are exercisable once vested. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:38 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 2,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037101 · doc4.xml · nonDerivative · entry 2 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,754 F2 · shares: The amount represents restricted stock units that vest in full on the earliest of June 12, 2021, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:38 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 1,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037101 · doc4.xml · nonDerivative · entry 1 Knobil Katharine · CIK 0001768011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,308 F1 · shares: The amount represents restricted stock units that vest in three equal installments on the dates of Arena's next three annual meetings of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 08:00 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 67,500 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010882 · doc4.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2030-04-14 F1 · derivative.exercise_date: 25% of this option shall vest on April 15, 2021, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:05 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantRestricted Stock Units · Derivative | 15,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006857 · doc4.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,843 Underlying: Common Stock · 15,843 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units shall vest 100% on February 28, 2022. F2 · derivative.expiration_date: The restricted stock units shall vest 100% on February 28, 2022. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 16:06 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-027504 · doc4.xml · derivative · entry 2 Knobil Katharine · CIK 0001768011 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The restricted stock units shall vest 50% on November 15, 2020, and the remaining 50% shall vest on November 15, 2021. F3 · derivative.expiration_date: The restricted stock units shall vest 50% on November 15, 2020, and the remaining 50% shall vest on November 15, 2021. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 16:06 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0000899243-19-027504 · doc4.xml · derivative · entry 1 Knobil Katharine · CIK 0001768011 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-11-14 F1 · derivative.exercise_date: 25% of this option shall vest November 15, 2020, with the remaining 75% vesting in equal quarterly installments over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.